//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
#Zasocitinib achieved >2.5x the PASI 100 rate of deucravacitinib in a head‑to‑head Phase 3 #psoriasis trial, with consistent safety and once‑daily oral dosing www.ipharmacenter.com/post/takeda-... #news #media #pharma #pharmaceutical #healthcare #globalhealth #lifesciences
17h
Takeda reports that its investigational oral therapy Zasocitinib achieved markedly stronger outcomes than deucravacitinib in a head-to-head Phase 3 trial in adults with moderate to severe plaque psori...
www.ipharmacenter.com
Takeda's Zasocitinib achieved over 2.5 times the PASI 100 rate of deucravacitinib in a head‑to‑head Ph3 psoriasis trial | iPharmaCenter